|
20.01.2005 15:03:00
|
GE Healthcare: New Research Provides Unprecedented Insight into Gene R
GE Healthcare: New Research Provides Unprecedented Insight into Gene Response Following Myocardial Infarction Allegheny General Hospital Utilizes GE Healthcare's CodeLink(TM) System to Advance Cardiovascular Research and Development
In the most comprehensive study of its kind, researchers at Allegheny General Hospital in Pittsburgh, Pennsylvania using GE Healthcare's CodeLink(TM) have gathered significant data shedding new light on the important gene expression changes that occur in the heart following myocardial infarction (MI). Data gathered from this study were published in the January issue of the Journal of Molecular and Cellular Cardiology.
"The results of this study raise the possibility of developing revolutionary new treatments to minimize the impact of MI. Understanding in more detail the complex pattern of the changes activated by myocardial injury will allow the medical community to develop therapies that may preserve heart muscle before it deteriorates," said Dr. Robert Guthrie, Director, Division of Neonatology, Allegheny General Hospital and Professor of Pediatrics, Drexel University School of Medicine. "A key component in our research was the CodeLink system, which allowed us to advance previous research through its highly sensitive microarrays and improved techniques for detecting slight yet critical changes in gene expression. Importantly, CodeLink was technically precise, but did not burden our research with complex informatics, making the data easier for us to understand and interpret internally."
In addition to Dr. Guthrie, other key contributors to the study include William LaFramboise, Ph.D., Department of Cardiothoracic Surgery at Allegheny General Hospital and Department of Pathology, University of Pittsburgh School of Medicine, and James Magovern, M.D., Director of Cardiac Surgery and Cardiac Surgery Research at Allegheny General Hospital.
A major finding of the study was that genes affected by a MI are not deactivated; rather they attempt to repair and rejuvenate in the area of the heart that was affected. Myocardial infarction, also known as a heart attack, occurs when the blood supply to part of the heart muscle itself -- the myocardium -- is severely reduced or stopped. If the blood supply is cut off for more than a few minutes, muscle cells suffer permanent injury and die. This can kill or disable someone, depending on how much heart muscle is damaged. Cardiovascular disease (CVD) is the number one killer in the United States. Of the 64,400,000 Americans with one or more types of CVD, approximately 7,800,000 experience MI.(1)
This preclinical study was undertaken to outline the multiple molecular processes that occur in the heart following a MI. Successful MI compensation involved early remote zone gene activation including an acute phase response, initiation of a cytoprotective program, recruitment of extensive developmental transcription factors and induction of signaling pathways associated with cell proliferation. Despite overriding transcriptional depression, the infarct zone exhibited an early cytoprotective response through recruitment of different gene families than the remote zone. By Day 28, the infarct zone adopted a strategy mirroring the early remote zone including expression of developmental transcription factors, proliferation signals, and matrix repair processes.
Critical components that aided researchers in this discovery was the use of GE Healthcare's CodeLink microarrays, which offered researchers higher sensitivity microarrays, and improved techniques for high-fidelity RNA amplification from small samples.
"The ability to identify even slight gene expression changes can have a huge impact on researcher's understanding of the cellular processes involved in the onset and cascade of a disease," said Chockalingam Palaniappan, Head of R&D in the Molecular Diagnostics division, GE Healthcare. "GE is pleased that its technologies, including the CodeLink UniSet Rat 10K Bioarray used in this study, are continually assisting researchers to make significant strides in preclinical research which will pave the way for better medical care in the future."
(1) American Heart Association: Heart Disease and Stroke Statistics--2004 Update
About CodeLink
The CodeLink Bioarray enables researchers to compare the expression level of thousands of genes in a single experiment, rather than examining individual gene activities one at a time. CodeLink Bioarrays utilize patented 3-D matrix technology along with functionally validated genes to offer the most reproducible, sensitive and reliable microarrays available.
About Allegheny General Hospital
Allegheny General Hospital is an 829-bed academic health center serving Pittsburgh and the surrounding five-state area. Along with its Suburban Campus, the hospital annually admits nearly 32,000 patients, and approximately 1,250 physicians and nearly 4,600 employees share Allegheny General's commitment to excellence in patient care, medical education and research. A member of the West Penn Allegheny Health System, Allegheny General Hospital is an affiliate site for the Philadelphia-based Drexel University College of Medicine; third- and fourth-year medical students receive clinical training at the hospital.
About GE Healthcare
GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceutical manufacturing technologies is dedicated to detecting disease earlier and tailoring treatment for individual patients. GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer's and cardiovascular diseases.
GE Healthcare is a $14 billion unit of General Electric Company (NYSE:GE) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit www.gehealthcare.com.
--30--JG/lo*
Business Editors/Health/Medical Writers
BIOWIRE2K
CHALFONT ST GILES, England--(BUSINESS WIRE)--Jan. 20, 2005--
In the most comprehensive study of its kind, researchers at Allegheny General Hospital in Pittsburgh, Pennsylvania using GE Healthcare's CodeLink(TM) have gathered significant data shedding new light on the important gene expression changes that occur in the heart following myocardial infarction (MI). Data gathered from this study were published in the January issue of the Journal of Molecular and Cellular Cardiology.
"The results of this study raise the possibility of developing revolutionary new treatments to minimize the impact of MI. Understanding in more detail the complex pattern of the changes activated by myocardial injury will allow the medical community to develop therapies that may preserve heart muscle before it deteriorates," said Dr. Robert Guthrie, Director, Division of Neonatology, Allegheny General Hospital and Professor of Pediatrics, Drexel University School of Medicine. "A key component in our research was the CodeLink system, which allowed us to advance previous research through its highly sensitive microarrays and improved techniques for detecting slight yet critical changes in gene expression. Importantly, CodeLink was technically precise, but did not burden our research with complex informatics, making the data easier for us to understand and interpret internally."
In addition to Dr. Guthrie, other key contributors to the study include William LaFramboise, Ph.D., Department of Cardiothoracic Surgery at Allegheny General Hospital and Department of Pathology, University of Pittsburgh School of Medicine, and James Magovern, M.D., Director of Cardiac Surgery and Cardiac Surgery Research at Allegheny General Hospital.
A major finding of the study was that genes affected by a MI are not deactivated; rather they attempt to repair and rejuvenate in the area of the heart that was affected. Myocardial infarction, also known as a heart attack, occurs when the blood supply to part of the heart muscle itself -- the myocardium -- is severely reduced or stopped. If the blood supply is cut off for more than a few minutes, muscle cells suffer permanent injury and die. This can kill or disable someone, depending on how much heart muscle is damaged. Cardiovascular disease (CVD) is the number one killer in the United States. Of the 64,400,000 Americans with one or more types of CVD, approximately 7,800,000 experience MI.(1)
This preclinical study was undertaken to outline the multiple molecular processes that occur in the heart following a MI. Successful MI compensation involved early remote zone gene activation including an acute phase response, initiation of a cytoprotective program, recruitment of extensive developmental transcription factors and induction of signaling pathways associated with cell proliferation. Despite overriding transcriptional depression, the infarct zone exhibited an early cytoprotective response through recruitment of different gene families than the remote zone. By Day 28, the infarct zone adopted a strategy mirroring the early remote zone including expression of developmental transcription factors, proliferation signals, and matrix repair processes.
Critical components that aided researchers in this discovery was the use of GE Healthcare's CodeLink microarrays, which offered researchers higher sensitivity microarrays, and improved techniques for high-fidelity RNA amplification from small samples.
"The ability to identify even slight gene expression changes can have a huge impact on researcher's understanding of the cellular processes involved in the onset and cascade of a disease," said Chockalingam Palaniappan, Head of R&D in the Molecular Diagnostics division, GE Healthcare. "GE is pleased that its technologies, including the CodeLink UniSet Rat 10K Bioarray used in this study, are continually assisting researchers to make significant strides in preclinical research which will pave the way for better medical care in the future."
(1) American Heart Association: Heart Disease and Stroke Statistics--2004 Update
About CodeLink
The CodeLink Bioarray enables researchers to compare the expression level of thousands of genes in a single experiment, rather than examining individual gene activities one at a time. CodeLink Bioarrays utilize patented 3-D matrix technology along with functionally validated genes to offer the most reproducible, sensitive and reliable microarrays available.
About Allegheny General Hospital
Allegheny General Hospital is an 829-bed academic health center serving Pittsburgh and the surrounding five-state area. Along with its Suburban Campus, the hospital annually admits nearly 32,000 patients, and approximately 1,250 physicians and nearly 4,600 employees share Allegheny General's commitment to excellence in patient care, medical education and research. A member of the West Penn Allegheny Health System, Allegheny General Hospital is an affiliate site for the Philadelphia-based Drexel University College of Medicine; third- and fourth-year medical students receive clinical training at the hospital.
About GE Healthcare
GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceutical manufacturing technologies is dedicated to detecting disease earlier and tailoring treatment for individual patients. GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer's and cardiovascular diseases.
GE Healthcare is a $14 billion unit of General Electric Company (NYSE:GE) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit www.gehealthcare.com.
--30--JG/lo*
CONTACT: GE Healthcare Helen Longvill, +44 (0) 1494 498 050 Kristin Silady, +1 732 457 8149 or Allegheny General Hospital Dan Laurent, +1 412 359 8602
KEYWORD: PENNSYLVANIA UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY PRODUCT SOURCE: GE Healthcare
Copyright Business Wire 2005
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu General Electric Co.mehr Nachrichten
Analysen zu General Electric Co.mehr Analysen
Indizes in diesem Artikel
| Dow Jones | 44 421,91 | -0,28% | |
| S&P 500 | 5 994,57 | -0,76% | |
| S&P 100 | 2 923,95 | -0,92% | |
| NYSE US 100 | 17 225,74 | -0,67% |
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.